Increased survival due to lower toxicity for high-risk T-cell acute lymphoblastic leukemia patients in two consecutive pediatric-inspired PETHEMA trials.

Pere BarbaMireia MorgadesPau MontesinosCristina GilMaría-Laura FoxJuana CiudadMaría-José MorenoJosé González-CamposEulàlia GenescàDaniel Martínez-CarballeiraRodrigo MartinoSusana VivesRamon GuardiaSantiago MercadalMaría-Teresa ArtolaAntonia CladeraMar TormoJordi EsteveJuan BerguaFerran Vall-LloveraJordi RiberaPilar Martínez-SanchezMaría-Luz AmigoArantxa BermúdezMaría CalbachoJesús-Maria Hernández-RivasEvaristo FeliuAlberto OrfaoJosep-María Ribera

Published in: European journal of haematology (2018)

Patients with T-cell ALL included in the HR-11 trial showed better OS than patients in the HR-03, mostly driven by a reduction of NRM.

Keyphrases

acute lymphoblastic leukemia
end stage renal disease
ejection fraction
newly diagnosed
randomized controlled trial
study protocol
acute myeloid leukemia
phase ii